| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.08 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.055 | 0.09 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.09 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.09 |